The rise of copyright’s blockbuster initially drove a boom for pharma, however recent changes present a uncertain scenario for shareholders. Off-patent versions are reducing profits, and persistent legal battles add https://aprilkena928602.theideasblog.com/41650125/the-blue-pill-and-pharma-a-volatile-investment